MacroGenics appoints Emil Kuriakose and Michael Vasconcelles as independent directors
MGNX•MacroGenics appointed Emil Kuriakose and Michael Vasconcelles as independent directors, effective October 30, 2026.
1. Board appointments
Kuriakose most recently served as chief medical officer at Terns Pharmaceuticals, leading clinical development and portfolio strategy. Vasconcelles most recently served as head of research and development at Day One Biopharmaceuticals, helping expand its pipeline.
